Abstract
In the past decade, toxic uremic solutes in the molecular range of 350–5000 daltons, so called middle molecules (mm), have received much attention, particularly with regard to determination of their chemical structure and biologic toxicity (1–5). Even though substantial proof is still incomplete, uremic toxins with mm have been increasingly identified. In recent years, several new mm compounds have been fractioned and isolated in increased amounts in uremic sera and have been found to be responsible for the clinical manifestations (6–8). The present study is to ascertain the value of quantitative analysis of mm in the evaluation of the efficacy of continuous ambulatory peritoneal dialysis (CAPD), hemodialysis (HD), sequential ultrafiltration and diffusion dialysis (SUD), hemofiltration (HF), hemoperfusion (HP) and reused hollow fiber dialysers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bergström J., Asaba H., Fürst P., Gordon A., Quadracci L., Zimmerman L.,: Middle molecules in uremia. In 6th International Congress of nephrology, edited by Qiovannetti S., Bonomini V., D’Amico G., SKarger, Basel 1976, p. 600.
Fürst P., Zimmerman L., Bergslröm J.: Determination of endogenous middle molecules in normal and uremic body fluids. Clin. Nephrol. 5,178 1976.
Man NK., Uremic neurotoxin in the middle molecular weight range. Artif. Organs 4:116 1980.
Ringoir S., Van Landschoot N., de Smet R., Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate. Clin. Nephrol. 13:109,1980.
Dzurik R., Hupkova V., Valovicova E.: Metabolic actions of middle molecules. Arüf. Organs 4(Suppl): 59 1980.
Asaba H., Alvestrand A., Bergström J., Fürst P., Yahiel V., Uremic middle molecules in non-dialyzed azotemic patients: relation to symptoms and clinical biochemistries. Clin. Nephrol. 17:90 1982.
Gallice P., Founier N., Crevat A., Briot M., Frayssinet R., Murisasco A.: Separation of one uremic middle molecules fraction by high performance liquid chromatography. Kidney Int. 23:764 1983.
Zimmerman L., Bergström J., Jornvall H. A method for separation of middle molecules by high performance liquid chromatography: application in studies of glucuronyl-o-hydroxyhippurate in normal and uremic subjects. Clin. Nephrol. 25:94,1986
Wu ZG, Cai ZH, Lu ZN, Liao LT, Zhu SQ: Determination of middle molecules in uremic patients. Chinesse med. J. (English ed.) 98:115 1985.
de Wardener HE, Macgregor OA: The relation of a circulating sodium transport inhibitor (the natriuretic hormome?) to hypertension medicine 62: 310 1983.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Press, New York
About this chapter
Cite this chapter
Wu, ZG., Liao, LT., Cai, ZH., Lu, ZN., Cai, YD., Sheng, PF. (1987). Middle Molecules as a Marker of Uremic Toxins. In: Ringoir, S., Vanholder, R., Massry, S.G. (eds) Uremic Toxins. Advances in Experimental Medicine and Biology, vol 223. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5445-1_4
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5445-1_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5447-5
Online ISBN: 978-1-4684-5445-1
eBook Packages: Springer Book Archive